Wordt geladen...
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 o...
Bewaard in:
| Gepubliceerd in: | Cancer Manag Res |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935287/ https://ncbi.nlm.nih.gov/pubmed/31920387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S212559 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|